BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, founded in 1986, specializes in developing novel medicines for rare diseases and operates globally, with headquarters in Durham, North Carolina.
History
BioCryst Pharmaceuticals was founded in 1986 from the labs of the University of Alabama at Birmingham. Over the years, it has evolved into a fully integrated biotech company focused on developing medicines for rare diseases. The company has expanded its operations globally, marking its presence in multiple countries across North America, Europe, and Asia.
Services
BioCryst Pharmaceuticals specializes in developing innovative medicines for complement-mediated and other rare diseases. Utilizing a structure-guided drug design approach, the company aims to create targeted treatments that address unmet medical needs. BioCryst also offers expanded access programs for investigational medicines, ensuring access to cutting-edge treatments under specific conditions.
Products
BioCryst Pharmaceuticals offers several notable products, including ORLADEYO (berotralstat), specifically for hereditary angioedema, and RAPIVAB (peramivir injection), an antiviral treatment. These products exemplify the company's focus on providing therapeutic solutions for rare and unmet medical needs.
Global Operations
BioCryst Pharmaceuticals operates on a global scale, featuring regional websites for multiple countries and extending its reach to markets including Canada, Denmark, Finland, France, Germany, Italy, Japan, Norway, Spain, Sweden, and the United Kingdom. The company is headquartered in Durham, North Carolina, with additional pivotal locations: a Discovery Center of Excellence in Birmingham, Alabama, and European headquarters in Dublin, Ireland.
Research and Partnerships
Engagement in research and collaboration is a cornerstone of BioCryst Pharmaceuticals' strategy. The company supports various research partnerships and external research programs, enhancing its scientific and medical capabilities. By fostering these collaborations, BioCryst aims to advance the development of novel therapeutics for rare diseases.